| Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. | |
| | |
MedLine Citation:
|
PMID: 19707816 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Neoangiogenesis has been documented in small cell lung carcinoma (SCLC). In addition, antiangiogenic therapies are being tested in clinical trials that involve SCLC. However, study of the underlying mechanisms has been performed almost exclusively in cell lines. In the current study, we immunostained 30 biopsy samples of SCLC with antibodies to hypoxia inducible factor-1 alpha (HIF-1 alpha), vascular endothelial growth factor (VEGF), vascular endothelial growth factor-receptor 1 (VEGF-R1/flt-1) and vascular endothelial growth factor-receptor 2 (VEGF-R1/flk-1). The immunoreactivity was analyzed using a bivariate Spearman correlation test and linear regression analysis. We found significant correlation between HIF-1 alpha nuclear staining and VEGF staining. Moreover HIF-1 alpha+/VEGF+ cases were associated with poor survival. We also found a positive correlation between VEGF and VEGF-R2 expression. We suggest that a HIF-1 alpha/VEGF angiogenic pathway may exist in vivo in SCLC, similar to that in non-SCLC. Our data also suggest a potential VEGF/VEGFR-2 autocrine pathway in SCLC. The inclusion of novel inhibitors to HIF-1 alpha and other factors may optimize antiangiogenic interventions in SCLC. |
| | |
Authors:
|
M Ioannou; R Papamichali; E Kouvaras; I Mylonis; D Vageli; T Kerenidou; S Barbanis; A Daponte; G Simos; K Gourgoulianis; G K Koukoulis |
Publication Detail:
|
Type: Journal Article Date: 2009-08-26 |
Journal Detail:
|
Title: Lung Volume: 187 ISSN: 1432-1750 ISO Abbreviation: Lung Publication Date: 2009 Sep-Oct |
Date Detail:
|
Created Date: 2009-09-16 Completed Date: 2009-12-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7701875 Medline TA: Lung Country: United States |
Other Details:
|
Languages: eng Pagination: 321-9 Citation Subset: IM |
Affiliation:
|
Department of Pathology, Medical School, University of Thessaly, Mezourlo, Larissa, 41110, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Biopsy Female Humans Hypoxia-Inducible Factor 1, alpha Subunit / analysis* Immunohistochemistry Kaplan-Meiers Estimate Linear Models Lung Neoplasms / blood supply, chemistry*, mortality, pathology, therapy Male Middle Aged Neoplasm Staging Proportional Hazards Models Risk Assessment Small Cell Lung Carcinoma / blood supply, chemistry*, mortality, pathology, therapy Time Factors Treatment Outcome Vascular Endothelial Growth Factor A / analysis* Vascular Endothelial Growth Factor Receptor-1 / analysis Vascular Endothelial Growth Factor Receptor-2 / analysis |
| Chemical | |
Reg. No./Substance:
|
0/HIF1A protein, human; 0/Hypoxia-Inducible Factor 1, alpha Subunit; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; EC 2.7.10.1/FLT1 protein, human; EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Implementing fast-track protocol for colorectal surgery: a prospective randomized clinical trial.
Next Document: Disturbances of esophageal motility in eosinophilic esophagitis: a case series.